Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 10 of 32

Publication Record


Stimulation of entorhinal cortex-dentate gyrus circuitry is antidepressive.
Yun S, Reynolds RP, Petrof I, White A, Rivera PD, Segev A, Gibson AD, Suarez M, DeSalle MJ, Ito N, Mukherjee S, Richardson DR, Kang CE, Ahrens-Nicklas RC, Soler I, Chetkovich DM, Kourrich S, Coulter DA, Eisch AJ
(2018) Nat Med 24: 658-666
MeSH Terms: Animals, Antidepressive Agents, Behavior, Animal, Chronic Disease, Dendrites, Dentate Gyrus, Entorhinal Cortex, Glutamates, HEK293 Cells, Humans, Membrane Proteins, Mice, Inbred C57BL, Mice, Knockout, Nerve Net, Neurogenesis, Peroxins, Stress, Psychological
Show Abstract · Added April 2, 2019
Major depressive disorder (MDD) is considered a 'circuitopathy', and brain stimulation therapies hold promise for ameliorating MDD symptoms, including hippocampal dysfunction. It is unknown whether stimulation of upstream hippocampal circuitry, such as the entorhinal cortex (Ent), is antidepressive, although Ent stimulation improves learning and memory in mice and humans. Here we show that molecular targeting (Ent-specific knockdown of a psychosocial stress-induced protein) and chemogenetic stimulation of Ent neurons induce antidepressive-like effects in mice. Mechanistically, we show that Ent-stimulation-induced antidepressive-like behavior relies on the generation of new hippocampal neurons. Thus, controlled stimulation of Ent hippocampal afferents is antidepressive via increased hippocampal neurogenesis. These findings emphasize the power and potential of Ent glutamatergic afferent stimulation-previously well-known for its ability to influence learning and memory-for MDD treatment.
0 Communities
1 Members
0 Resources
17 MeSH Terms
Intracardiac Metastases Detected by 18F-FSPG PET/CT.
Magarik MA, Walker RC, Gilbert J, Manning HC, Massion PP
(2018) Clin Nucl Med 43: 28-30
MeSH Terms: Carcinoma, Non-Small-Cell Lung, Female, Glutamates, Heart Neoplasms, Humans, Lung Neoplasms, Middle Aged, Positron Emission Tomography Computed Tomography
Show Abstract · Added January 29, 2018
PET/CT imaging is frequently used for cancer diagnosis and restaging as metabolically active cells, including cancer, utilize glucose for proliferation. F-FDG is the most commonly utilized radiopharmaceutical in PET/CT imaging. Limitations of F-FDG imaging include intense physiologic uptake in benign tissues such as the brain and myocardium. We present a case of non-small cell lung cancer with myocardial and pericardial metastases obscured by physiologic F-FDG cardiac uptake but detected with the investigational PET radiotracer (4S)-4-(3-F-fluoropropyl)-L-glutamate (F-FSPG), which targets a pathway associated with glutathione biosynthesis. This case demonstrates the added value of F-FSPG PET/CT imaging.
0 Communities
2 Members
0 Resources
8 MeSH Terms
Endocannabinoid signalling modulates susceptibility to traumatic stress exposure.
Bluett RJ, Báldi R, Haymer A, Gaulden AD, Hartley ND, Parrish WP, Baechle J, Marcus DJ, Mardam-Bey R, Shonesy BC, Uddin MJ, Marnett LJ, Mackie K, Colbran RJ, Winder DG, Patel S
(2017) Nat Commun 8: 14782
MeSH Terms: Amygdala, Animals, Anxiety, Arachidonic Acids, Behavior, Animal, Benzodioxoles, Disease Susceptibility, Dronabinol, Endocannabinoids, Excitatory Postsynaptic Potentials, Female, Glutamates, Glycerides, Hippocampus, Lipoprotein Lipase, Male, Mice, Inbred ICR, Mice, Knockout, Phenotype, Piperidines, Resilience, Psychological, Signal Transduction, Stress, Psychological, Synapses
Show Abstract · Added April 7, 2017
Stress is a ubiquitous risk factor for the exacerbation and development of affective disorders including major depression and posttraumatic stress disorder. Understanding the neurobiological mechanisms conferring resilience to the adverse consequences of stress could have broad implications for the treatment and prevention of mood and anxiety disorders. We utilize laboratory mice and their innate inter-individual differences in stress-susceptibility to demonstrate a critical role for the endogenous cannabinoid 2-arachidonoylglycerol (2-AG) in stress-resilience. Specifically, systemic 2-AG augmentation is associated with a stress-resilient phenotype and enhances resilience in previously susceptible mice, while systemic 2-AG depletion or CB1 receptor blockade increases susceptibility in previously resilient mice. Moreover, stress-resilience is associated with increased phasic 2-AG-mediated synaptic suppression at ventral hippocampal-amygdala glutamatergic synapses and amygdala-specific 2-AG depletion impairs successful adaptation to repeated stress. These data indicate amygdala 2-AG signalling mechanisms promote resilience to adverse effects of acute traumatic stress and facilitate adaptation to repeated stress exposure.
0 Communities
4 Members
0 Resources
24 MeSH Terms
Utility of [F]FSPG PET to Image Hepatocellular Carcinoma: First Clinical Evaluation in a US Population.
Kavanaugh G, Williams J, Morris AS, Nickels ML, Walker R, Koglin N, Stephens AW, Washington MK, Geevarghese SK, Liu Q, Ayers D, Shyr Y, Manning HC
(2016) Mol Imaging Biol 18: 924-934
MeSH Terms: Acetates, Adult, Aged, Amino Acid Transport System y+, Carbon Radioisotopes, Carcinoma, Hepatocellular, Female, Glutamates, Glutamic Acid, Humans, Liver Neoplasms, Male, Middle Aged, Positron-Emission Tomography, Radiopharmaceuticals, Sequence Analysis, RNA, Tissue Array Analysis
Show Abstract · Added April 6, 2017
PURPOSE - Non-invasive imaging is central to hepatocellular carcinoma (HCC) diagnosis; however, conventional modalities are limited by smaller tumors and other chronic diseases that are often present in patients with HCC, such as cirrhosis. This pilot study evaluated the feasibility of (4S)-4-(3-[F]fluoropropyl)-L-glutamic acid ([F]FSPG) positron emission tomography (PET)/X-ray computed tomography (CT) to image HCC. [F]FSPG PET/CT was compared to standard-of-care (SOC) magnetic resonance imaging (MRI) and CT, and [C]acetate PET/CT, commonly used in this setting. We report the largest cohort of HCC patients imaged to date with [F]FSPG PET/CT and present the first comparison to [C]acetate PET/CT and SOC imaging. This study represents the first in a US HCC population, which is distinguished by different underlying comorbidities than non-US populations.
PROCEDURES - x transporter RNA and protein levels were evaluated in HCC and matched liver samples from The Cancer Genome Atlas (n = 16) and a tissue microarray (n = 83). Eleven HCC patients who underwent prior MRI or CT scans were imaged by [F]FSPG PET/CT, with seven patients also imaged with [C]acetate PET/CT.
RESULTS - x transporter RNA and protein levels were elevated in HCC samples compared to background liver. Over 50 % of low-grade HCCs and ~70 % of high-grade tumors exceeded background liver protein expression. [F]FSPG PET/CT demonstrated a detection rate of 75 %. [F]FSPG PET/CT also identified an HCC devoid of typical MRI enhancement pattern. Patients scanned with [F]FSPG and [C]acetate PET/CT exhibited a 90 and 70 % detection rate, respectively. In dually positive tumors, [F]FSPG accumulation consistently resulted in significantly greater tumor-to-liver background ratios compared with [C]acetate PET/CT.
CONCLUSIONS - [F]FSPG PET/CT is a promising modality for HCC imaging, and larger studies are warranted to examine [F]FSPG PET/CT impact on diagnosis and management of HCC. [F]FSPG PET/CT may also be useful for phenotyping HCC tumor metabolism as part of precision cancer medicine.
0 Communities
2 Members
0 Resources
17 MeSH Terms
M4 mAChR-mediated modulation of glutamatergic transmission at corticostriatal synapses.
Pancani T, Bolarinwa C, Smith Y, Lindsley CW, Conn PJ, Xiang Z
(2014) ACS Chem Neurosci 5: 318-24
MeSH Terms: Animals, Cerebral Cortex, Cholinergic Neurons, Corpus Striatum, Glutamates, Male, Mice, Mice, Inbred C57BL, Neural Inhibition, Neural Pathways, Receptor, Muscarinic M4, Synapses, Synaptic Transmission
Show Abstract · Added February 19, 2015
The striatum is the main input station of the basal ganglia and is extensively involved in the modulation of motivated behavior. The information conveyed to this subcortical structure through glutamatergic projections from the cerebral cortex and thalamus is processed by the activity of several striatal neuromodulatory systems including the cholinergic system. Acetylcholine potently modulates glutamate signaling in the striatum via activation of muscarinic receptors (mAChRs). It is, however, unclear which mAChR subtype is responsible for this modulatory effect. Here, by using electrophysiological, optogenetic, and immunoelectron microscopic approaches in conjunction with a novel, highly selective M4 positive allosteric modulator VU0152100 (ML108) and M4 knockout mice, we show that M4 is a major mAChR subtype mediating the cholinergic inhibition of corticostriatal glutamatergic input on both striatonigral and striatopallidal medium spiny neurons (MSNs). This effect is due to activation of presynaptic M4 receptors, which, in turn, leads to a decrease in glutamate release from corticostriatal terminals. The findings of the present study raise the interesting possibility that M4 mAChR could be a novel therapeutic target for the treatment of neurological and neuropsychiatric disorders involving hyper-glutamatergic transmission at corticostriatal synapses.
0 Communities
1 Members
0 Resources
13 MeSH Terms
An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers.
Wen Y, Gamazon ER, Bleibel WK, Wing C, Mi S, McIlwee BE, Delaney SM, Duan S, Im HK, Dolan ME
(2012) Hum Mol Genet 21: 1470-80
MeSH Terms: Antineoplastic Agents, Carrier Proteins, Cell Line, Tumor, Cortactin, Gene Expression, Genome-Wide Association Study, Glutamates, Guanine, Humans, Linear Models, Lymphocytes, Nuclear Proteins, Pemetrexed, Polymorphism, Single Nucleotide, Quantitative Trait Loci, RNA-Binding Proteins
Show Abstract · Added April 13, 2017
Pemetrexed, approved for the treatment of non-small cell lung cancer and malignant mesothelioma, has adverse effects including neutropenia, leucopenia, thrombocytopenia, anemia, fatigue and nausea. The results we report here represent the first genome-wide study aimed at identifying genetic predictors of pemetrexed response. We utilized expression quantitative trait loci (eQTLs) mapping combined with drug-induced cytotoxicity data to gain mechanistic insights into the observed genetic associations with pemetrexed susceptibility. We found that CTTN and ZMAT3 expression signature explained >30% of the pemetrexed susceptibility phenotype variation for pemetrexed in the discovery population. Replication using PCR and a semi-high-throughput, scalable assay system confirmed the initial discovery results in an independent set of samples derived from the same ancestry. Furthermore, functional validation in both germline and tumor cells demonstrates a decrease in cell survival following knockdown of CTTN or ZMAT3. In addition to our particular findings on genetic and gene expression predictors of susceptibility phenotype for pemetrexed, the work presented here will be valuable to the robust discovery and validation of genetic determinants and gene expression signatures of various chemotherapeutic susceptibilities.
0 Communities
1 Members
0 Resources
16 MeSH Terms
Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer.
Gilbert J, Murphy B, Dietrich MS, Henry E, Jordan R, Counsell A, Wirth P, Yarbrough WG, Slebos RJ, Chung CH
(2012) Cancer 118: 1007-13
MeSH Terms: Adult, Aged, Antineoplastic Agents, Disease-Free Survival, Drug Therapy, Combination, Female, Glutamates, Guanine, Head and Neck Neoplasms, Humans, Induction Chemotherapy, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Staging, Organoplatinum Compounds, Outcome Assessment, Health Care, Oxaliplatin, Pemetrexed, Severity of Illness Index, Survival Rate, Treatment Outcome
Show Abstract · Added March 5, 2014
BACKGROUND - This phase 2 trial evaluated the tolerability and clinical efficacy of the combination of oxaliplatin and pemetrexed as an induction chemotherapy regimen in locally advanced head and neck squamous cell carcinoma (HNSCC).
METHODS - Forty-two patients were enrolled in the study. Patients received pemetrexed 300 mg/m(2) intravenously (IV) and oxaliplatin 85 mg/m(2) IV every 14 days for a total of 4 cycles. A subset of patients consented to correlative studies including tumor tissue for human papillomavirus (HPV) detection and expression of DNA repair genes that may be predictive of response or resistance to oxaliplatin or pemetrexed.
RESULTS - Response data were available for 40 patients. Eighteen had a partial response, and 1 had a complete response, for a response rate of 47.5%. Patients with HPV(+) disease demonstrated superior response rates, progression-free survival, and overall survival. The regimen was well tolerated, with predominantly grade 1 or 2 alanine aminotransferase/aspartate aminotransferase elevation. One patient had grade 5 toxicity with neutropenia and sepsis. The authors did not identify genes predictive of response or toxicity, although HPV(+) tumors demonstrated a unique gene expression signature.
CONCLUSIONS - Although the response rate of oxaliplatin and pemetrexed proved less than anticipated, the combination remains an active induction regimen in HNSCC. This regimen should be evaluated further in combination with targeted agents, such as cetuximab, especially in the HPV(+) patient population.
Copyright © 2011 American Cancer Society.
0 Communities
2 Members
0 Resources
22 MeSH Terms
mGluR4-positive allosteric modulation as potential treatment for Parkinson's disease.
Hopkins CR, Lindsley CW, Niswender CM
(2009) Future Med Chem 1: 501-13
MeSH Terms: Allosteric Regulation, Benzopyrans, Glutamates, Humans, Parkinson Disease, Receptors, Metabotropic Glutamate
Show Abstract · Added March 3, 2020
Although Parkinson's disease was first diagnosed nearly 200 years ago, its effective treatment still remains elusive for most of those diagnosed. The gold standard of treatment for most patients is 3,4-dihydroxy-L-phenylalanine. This drug works for most individuals early in the disease; however, resistant symptoms start to emerge after several years of treatment. There has been increased interest in finding novel therapies to help Parkinson's disease patients. Such strategies may have the benefit of not only treating the symptomatic issues of the disorder, but might also offer promise in protecting dopaminergic neurons from further degeneration. One such target that is now receiving much attention from the scientific community is the metabotropic glutamate receptor mGluR4. In this article, we briefly review Parkinson's disease and then recent work in the mGluR area, with a focus on the efforts being made toward finding and optimizing novel mGluR4 positive allosteric modulators (PAMs). Preclinically in rodent models, mGluR4 activation has offered much promise as a novel treatment of Parkinson's disease. Additionally, the specific use of PAMs, rather than direct-acting agonists at the orthosteric glutamate site, continues to be validated as a viable treatment option for this target. It is anticipated that continued progress in this area will further our understanding of the potential of mGluR4 modulation as a novel symptomatic and potentially disease-modifying treatment for Parkinson's disease.
0 Communities
1 Members
0 Resources
MeSH Terms
Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer.
Stover DG, Lockhart AC, Berlin JD, Chan E, Sandler AB, Sosman JA, Middlebrook V, Nicol S, Rothenberg ML
(2008) Invest New Drugs 26: 339-45
MeSH Terms: Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Dose-Response Relationship, Drug, Fatigue, Female, Glutamates, Guanine, Head and Neck Neoplasms, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Metastasis, Neutropenia, Organoplatinum Compounds, Oxaliplatin, Pemetrexed
Show Abstract · Added March 5, 2014
PURPOSE - To identify the maximum tolerated dose (MTD) and describe dose-limiting toxicities (DLT) of pemetrexed and oxaliplatin given on a once-every-2-week schedule in patients with metastatic cancer.
PATIENTS AND METHODS - Twenty-five patients were enrolled. Due to toxicities observed at the first dose level in unselected patients, a second MTD was determined in patients who had received zero to two prior chemotherapy regimens.
RESULTS - DLT was observed at dose level 1-pemetrexed 400 mg/m(2) and oxaliplatin 85 mg/m(2)-in the form of grade 3 fatigue in two of six patients. Enrollment was then limited to lightly pretreated patients and DLT was observed at dose level 2-pemetrexed 500 mg/m(2) and oxaliplatin 85 mg/m(2)-in the form of neutropenic fever in one of five patients. Complete response was confirmed in one patient (squamous cell carcinoma of the head and neck) and partial response was confirmed in three patients.
CONCLUSIONS - The combination of pemetrexed and oxaliplatin can be safely administered at doses of 400 to 500 mg/m(2) of pemetrexed and 85 mg/m(2) in patients without extensive prior therapy and 300 and 85 mg/m(2), respectively, every 2 weeks in patients with more extensive prior therapy. Based on promising results observed in this study, a phase II trial in patients with recurrent head and neck cancer has been initiated.
0 Communities
3 Members
0 Resources
19 MeSH Terms
Effects of naloxone-precipitated morphine withdrawal on glutamate-mediated signaling in striatal neurons in vitro.
Chartoff EH, Papadopoulou M, Konradi C, Carlezon WA
(2003) Ann N Y Acad Sci 1003: 368-71
MeSH Terms: Animals, Benzazepines, Cells, Cultured, Cyclic AMP Response Element-Binding Protein, Glutamates, Morphine Dependence, Naloxone, Narcotic Antagonists, Neostriatum, Neurons, Rats, Signal Transduction, Substance Withdrawal Syndrome
Added May 27, 2014
0 Communities
1 Members
0 Resources
13 MeSH Terms